Search clinical trials for: Batiraxcept

Total 5 results

Washington University School of Medicine
National Cancer Institute (NCI); Aravive, Inc.

Not yet recruiting

AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Recurrent High Grade Uterine Cancer

United States
Aravive, Inc.
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Terminated

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)

Platinum-resistant Ovarian Cancer

United States, Spain, Belgium, Canada, Georgia, Czechia, China, Poland, France, United Kingdom, Italy
Aravive, Inc.

Terminated

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States
Aravive, Inc.

Terminated

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
M.D. Anderson Cancer Center
AstraZeneca; Aravive Biologics Inc

Active, not recruiting

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States

Search clinical trials for: Batiraxcept

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations